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RETINAL LAYER RESPONSE TO
RANIBIZUMAB DURING TREATMENT
OF DIABETIC MACULAR EDEMA
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ANDREAS EBNETER, PHD, MD,*† SEBASTIAN WOLF, PHD, MD,*† JAIN ABHISHEK, MD,*
MARTIN S. ZINKERNAGEL, MD, PHD*†
Purpose: To identify individual retinal layer thickness changes associated with visual
acuity gain in diabetic macular edema treated with ranibizumab using layer segmentation
on high-resolution optical coherence tomography scans.
Methods: Retrospective observational case series. Thirty-three treatment-naive eyes
with diabetic macular edema were imaged by spectral domain optical coherence
tomography at monthly visits while receiving intravitreal ranibizumab treatment as needed,
guided by visual acuity. Thickness changes of individual layers after 1 year were
quantitatively analyzed and correlated with visual acuity gain.
Results: The mean best-corrected visual acuity improvement at 1 year was 6.2 (SEM ±
1.5) Early Treatment Diabetic Retinopathy Study letters, and central retinal thickness
decreased by 66 ± 18 mm. In the central subﬁeld, there was a signiﬁcant decrease of
thickness for all layers (P , 0.05) except the outer nuclear layer. Multiple linear regression
analysis revealed that thickness decrease of the inner retina was associated with better
visual acuity, whereas for the outer retina the opposite was true. The best estimate of ﬁnal
visual acuity (R2 = 0.817, P , 0.001) was obtained, by including baseline visual acuity and
thickness change of the inner and outer plexiform layers in the model.
Conclusion: Whereas thickness decrease of the inner retina was positively associated
with visual acuity gain, the opposite was found for the outer retina. This might be indirect
evidence for recovery of the outer retina during ranibizumab treatment.
RETINA 0:1–10, 2015
Diabetic retinopathy is the most common microvas-cular pathology in patients with diabetes. It is the
leading cause of blindness in working aged adults.1,2
Among patients with diabetic retinopathy, diabetic
macular edema (DME) is the most frequent cause of
vision impairment and affects nearly 30% of patients
who have diabetes for at least 20 years.3 Prolonged
hyperglycemia is the major etiologic driver of all
microvascular changes leading to DME. The cellular
mechanisms include thickening of the basement mem-
brane of the retinal capillaries, loss of intramural peri-
cytes, breakdown of the blood retina barrier as evident
from opening of the tight junctions, and chronic
microvascular inﬂammation with leukocyte-mediated
injury.4 This disruption of the blood–retina barrier
leads to intraretinal accumulation of ﬂuid and plasma
constituents such as lipoproteins.
In the last 20 years, noninvasive retinal imaging by
low-coherence interferometry has become an indispens-
able tool in the diagnosis of retinal diseases, as it allows
real-time visualization of the retina in great morpholog-
ical detail. The recent introduction of spectral domain
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optical coherence tomography has improved the under-
standing of the pathologic changes and related causes of
vision loss in many retinal diseases such as DME.5–7
With the introduction of anti-vascular endothelial
growth factor (anti-VEGF) agents for the treatment of
DME, total retinal thickness has often been used in
clinical trials as quantitative endpoint to monitor treat-
ment effectiveness.8–11 However, diabetes is primarily
a microvascular disease and as such ﬁrst leads to alter-
ations in the vascular supply and ischemia, which even-
tually may result in macular swelling and vision
impairment. Because the retina is supplied by two dif-
ferent vascular beds, namely the central retinal artery
with its end arteries and the choroidal circulation by
diffusion, there exists a watershed zone in the retina
and individual retinal layer changes might serve as a bio-
marker for response to treatment.12 In this context,
a recent report found an association between choroidal
thickness and the short-term response to anti-VEGF
treatment,13 and morphological evidence of foveal gan-
glion cell damage in patients with ischemic damage has
been reported.14 Using fully automated segmentation
software, we analyzed individual retinal layers in
treatment-naive eyes at baseline and after 1 year of con-
tinuous treatment with ranibizumab. After the initial
loading phase consisting of at least 3 monthly intravi-
treal injections until stability was reached, retreatment
was administered as needed, guided by visual acuity.
The investigated parameters might serve as useful
biomarkers to monitor intravitreal anti-VEGF treatment
for DME in daily practice and future clinical trials.
Methods
This study is a retrospective single-center observa-
tional case series. Ethics approval (KEK-Nr. 093/13)
was granted by the ethics committee of the University
of Bern, Switzerland, which works in accordance with
International Conference on Harmonisation of Good
Clinical Practice guidelines. The need for individual
written consent was waived because of the retrospec-
tive nature of the project.
Participants
One eye of consecutive adult diabetic patients
treated at our institution for center-involving DME
and deterioration of visual acuity requiring treatment
with anti-VEGF (ranibizumab) were included in this
analysis. If both eyes of a patient fulﬁlled the criteria
for inclusion, one eye was chosen randomly. All
patients had spectral domain optical coherence tomog-
raphy and ﬂuorescein angiography at baseline. Nine
eyes had concomitant ischemic maculopathy as
deﬁned previously.15 Only eyes naive to intravitreal
drug application at baseline with at least one year of
continuous ranibizumab treatment and follow-up were
included from the procedures log of the Retinal
Service of the Department of Ophthalmology at the
University Hospital Bern, Switzerland. Exclusion cri-
teria included previous macular laser, uncontrolled
glaucoma, or a history of intravitreal steroids. The
loading protocol was identical for all patients and con-
sisted of $3 monthly intravitreal injections of ranibi-
zumab 0.5 mg/0.05 mL until visual stability was
attained. Treatment was then suspended but reinitiated
if signs of new activation were detected, applying the
RESTORE stability and retreatment criteria.16
In addition to spectral domain optical coherence
tomography imaging, best-corrected visual acuity
(BCVA) was tested at baseline and monthly thereafter
on the Early Treatment Diabetic Retinopathy Study
(ETDRS) charts at 4 meters.
Image Acquisition
Spectral domain optical coherence tomography
(Spectralis HRA + OCT; Heidelberg Engineering
GmbH, Heidelberg, Germany) scans were serially
acquired in tracking mode using an established protocol
consisting of both a crosshair and a volume scan. The
volume scan, covering 20° · 20°, comprised 49 parallel
B-scans separated by 120 mm, whereby each B-scan
was the average of 9 frames (automated real time rep-
etition rate = 9), each consisting of 512 A-scans. For
retinal layer segmentation, the Heidelberg Eye Explorer
software (Version 1.9.10.0; Heidelberg Engineering
GmbH, Heidelberg, Germany) was used. The provided
standard ETDRS grid with central subﬁeld (r =
0.5 mm), inner ring (r = 0.5–1.5 mm), and outer ring
(r = 1.5–3 mm) was used for calculation of the mean
thickness of each retinal layer within the corresponding
areas. The Heidelberg Eye Explorer recognizes 11 dif-
ferent retinal tissue interfaces: the inner limiting mem-
brane, the boundaries between the retinal nerve ﬁber
layer and the ganglion cell layer (GCL), between the
GCL and the inner plexiform layer (IPL), between the
IPL and the inner nuclear layer (INL), between the INL
and the outer plexiform layer (OPL), between the OPL
and the outer nuclear layer (ONL), the external limiting
membrane, the ellipsoid zone, the interdigitation zone,
the retinal pigment epithelium (RPE), and Bruch’s
membrane with the underlying choroid. These land-
marks allow the software to handle the following retinal
layers: retinal nerve ﬁber layer, GCL, IPL, INL, OPL,
ONL, and the photoreceptor–RPE complex. Based on
the metabolic supply, the inner retina has been deﬁned
as the summation of retinal nerve ﬁber layer, GCL, IPL,
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and INL for some analyses in this study. The sum of the
remaining three layers (OPL, ONL, the photoreceptor–
RPE complex) is referred to as outer retina throughout
this article. Two experienced retina specialists reviewed
the retinal layer segmentation of each spectral domain
optical coherence tomography volume scan, and seg-
mentation lines were manually corrected.
Statistical Analysis
Study data were collected and managed using the
REDCap electronic data management tool hosted at
the Department of Ophthalmology, Bern University
Hospital, Switzerland.17 The last observation carried
forward method was used to substitute missing visual
acuity data. For statistical analysis, a commercial soft-
ware package (Prism 6; GraphPad Software Inc, La
Jolla, CA) was used. Serial changes were analyzed
using the Wilcoxon matched-pairs signed-rank test or
a paired Student’s t-test, depending on the distribution.
Possible predictive factors of BCVA at the last follow-
up and letter gain were identiﬁed by bivariate Pearson
correlation analysis. Subsequently, multivariate analy-
sis (ordinary least squares linear regression with step-
wise forward elimination) was performed with R
(Version 3.2.1) to conﬁrm parameters signiﬁcantly
associated with visual outcome.18–20 The number of
intravitreal injections, baseline BCVA, and 1-year
thickness decrease of all retinal layers were included
as potential explanatory variables. In the manuscript,
means are given with the standard error. All tests were
2-sided and P values , 0.05 were regarded as statis-
tically signiﬁcant.
Results
Thirty-three patients with treatment-naive DME that
were started on intravitreal ranibizumab were included
in this study. The mean age ±SEM of patients at ini-
tiation of treatment was 63.6 ± 2.1 years. The gender
distribution (20 males, 13 females) was deemed
acceptable and without inﬂuence on results. The mean
BCVA at baseline was 59.9 ± 2.8 ETDRS letters and
increased by an average of 6.2 ETDRS letters to
66.1 ± 2.7 at month 12 (P , 0.001; Figure 1A). Cen-
tral retinal thickness decreased from 425 ± 21 mm at
baseline to 359 ± 20 mm at month 12 (P , 0.001;
Figure 1B). The average total retinal thickness in the
inner ring decreased from 408 ± 15 mm at baseline to
366 ± 14 mm at one year (P , 0.001) and in the outer
ring from 345 ± 11 mm to 326 ± 9 mm (P , 0.001;
Figure 1C). On average, patients received 6 intravitreal
injections of ranibizumab in the ﬁrst year of treatment.
We analyzed the retinal layer segmentation data
(representative example in Figure 2A) to assess
whether particular layers differed in their response to
ranibizumab treatment. Within the ETDRS grid, there
was a signiﬁcant decrease of thickness in most layers
(Figure 2B). Of note, the ONL did not show a signif-
icant decrease in thickness in the central subﬁeld (P =
0.256). Figure 3 illustrates the situation for the IPL and
OPL in the inner and outer rings.
Associations of individual layer changes and other
potentially important explanatory variables were
explored in correlation matrices (Figure 4). Since the
Fig. 1. Visual acuity gain and reduction of central retinal thickness.
Mean change (±SEM) in BCVA from baseline (BL) to month 12 in
ETDRS letters (A). Mean change (±SEM) in central retinal thickness
(CRT) during treatment (B). Mean retinal thickness at baseline and 12
months (1 year) in the inner ring (IR) and the outer ring (OR) of the
standard ETDRS grid (C). Paired 2-sided Student’s t-test.
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strongest correlations with ﬁnal visual acuity were
found for the central subﬁeld (Figure 4A) and the inner
ring (Figure 4B), multivariate analysis was conducted
for these subsets of data.
Interestingly, the univariate analysis (Pearson corre-
lation) consistently indicated that decreasing thickness
of inner retina layers during treatment was associated
with better ﬁnal BCVA, whereas for the outer retina the
relationship was in reverse, in particular in the central
ETDRS subﬁeld. These ﬁndings were conﬁrmed in
multiple linear regression (Tables 1 and 2). However,
the strongest inﬂuence on ﬁnal BCVA had baseline
BCVA, contributing more than half to the coefﬁcient
of determination. The best multivariate linear model
(Table 1A) to predict ﬁnal BCVA included, apart from
baseline BCVA, thickness decrease of the IPL and OPL
in the central subﬁeld. The coefﬁcient of determination
R2 for this model was 0.817. The excellent ﬁt (P ,
0.001) is also evident in the model diagnostics analysis
Fig. 2. Retinal layer thickness changes. Representative optical coher-
ence tomogram scans showing layer segmentation at baseline (BL) (A1)
and at one-year (1 year) follow-up (A2). Retinal layer thickness at BL
and after 12 months of continuous treatment in the central subﬁeld (C;
B1), the inner ring (IR; B2), and the outer ring (OR; B3) of the ETDRS
grid. RNFL, retinal nerve ﬁber layer; GCL, ganglion cell layer; IPL,
inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform
layer; ONL, outer nuclear layer; PR, photoreceptor–RPE complex
(Bruch membrane to external limiting membrane). Two-sided paired
Student’s t-test and Wilcoxon matched-pairs signed-rank test (ns: P .
0.05; *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001).
Fig. 3. Response of the inner and outer plexiform layers. Top: Quantitative
thickness maps at baseline (BL) and at 1 year of treatment (1 year) for the
outer plexiform layer (OPL) within the standard ETDRS grid. Middle:
Corresponding optical coherence tomography scans (red lines delineate the
inner ring (IR) of the ETDRS grid) for OPL and inner plexiform layer
(IPL). Bottom: Bar graphs showing the average thickness (±SEM) of the
IPL and OPL at different time points in the IR and the outer ring (OR).
Two-sided paired Student’s t-test and Wilcoxon matched-pairs signed-rank
test (ns: P . 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001).
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(see Figure, Supplemental Digital Content 1, http://
links.lww.com/IAE/A414). Multivariate analysis was
also conducted for the ETDRS letter score change
(Table 3), with similar results. All models were also
calculated excluding baseline BCVA to better dissect
the inﬂuence of the individual retinal layers.
Discussion
Regular intravitreal treatment with ranibizumab has
been shown to result in reduced central retinal
thickness and improved BCVA in eyes with DME.16
Interestingly, in the current retrospective study, visual
acuity improvement was negatively associated with
the decrease of thickness of the outer retina. At ﬁrst
glance, this seems paradoxical. Anti-VEGFs are most
effective at blocking VEGF, arguably the most potent
mediator of blood–retina barrier breakdown,21 and
restore capillary integrity reliably. Reduced vascular
leakage results in resolution of retinal ﬂuid. Dimin-
ished retinal layer thickness would be the obvious
consequence, which indeed is observed in most layers
and associated with improved visual acuity. How
could it be that the outer retina behaves differently
from the inner retina? Could this paradox of the outer
retina be a sign of neurorecovery?22
The metabolic supply of the retina from the central
retinal artery has some peculiarities. The inner retina is
supplied by four capillary networks that are located in
distinct anatomical regions: the nerve ﬁber layer, the
GCL, and the boundaries of the INL towards the IPL
and OPL, respectively.23 The metabolic needs of the
outer retina, however, are mostly met by diffusion
from the choriocapillaris. The ONL, which contains
mainly photoreceptors, the most metabolically active
cells in the retina, is a watershed zone and hence prone
to hypoxia.24 In fact, photoreceptors are particularly
susceptible to hypoxia25 and functional deﬁcits are
reversible through additional oxygen or glucose sup-
ply.26 The increased diffusion path caused by retinal
thickening of the inner layers, the breakdown of the
outer blood retina barrier and if present, subretinal
ﬂuid, likely deteriorates the metabolic situation of
the outer retina.27,28 In detached retina, the ONL thick-
ness decreases29 and partially recovers after successful
retinal detachment repair in a time-dependent man-
ner.30 We hypothesize that, in analogy to starving
outer retina in retinal detachment, the ONL thickness
might decrease in DME. Through improvement of the
metabolic supply mediated by resolution of subretinal
ﬂuid, restoration of the outer blood retina barrier and
drying of the inner layers, viable photoreceptor that
have not yet passed the apoptotic threshold might
recover and their somata regain their normal size.
However, photoreceptors that have already gone into
apoptosis will not recuperate and follow their fate to
death. This would explain why a decrease of outer
retina thickness is negatively associated with better
ﬁnal BCVA. To gain some indirect information on
the health of the OPL and ONL in this cohort of pa-
tients, it seemed interesting to compare their thickness
with normal controls or other pathology with macular
swelling. Unfortunately, there are neither data on indi-
vidual layer thickness in DME nor normative values
for elderly individuals published. Comparison was
therefore made with some data from younger volun-
teers (see Table, Supplemental Digital Content 2,
Fig. 4. Correlation plots for individual layer thickness decrease and other parameters. Graphical display of correlation matrices (Pearson’s r) for
analyzed parameters in speciﬁed areas: ﬁnal BCVA, BL BCVA, number of IVTs, layer thickness decrease for RNFL, GCL, IPL, INL, OPL, ONL, PR.
Pair-wise correlations are presented numerically with Pearson’s r and corresponding P value (below diagonal), and color-size coded (above diagonal)
according to the legend on the right. Only signiﬁcant correlations are shown graphically (signiﬁcance level P , 0.05) and signiﬁcant P values are
marked with *. BL, Baseline; IVTs, intravitreal injections; RNFL, retinal nerve ﬁber layer; PR, photoreceptor–RPE complex.
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Table 1. Central Subﬁeld: Multivariate Forward Stepwise Regression Analysis of Factors With Inﬂuence on BCVA at the Last Follow-up in Eyes With DME Treated
With Ranibizumab
A
Univariate Analysis (Pearson
Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.817)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.366)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 20.064 — ,0.001 63.050 — ,0.001
BL BCVA 0.845 ,0.001 0.766 0.795 ,0.001
IVTs 0.141 0.435
Age −0.240 0.178
GCL 0.203 0.258
IPL 0.252 0.157 0.184 0.236 0.004
INL 0.503 0.003 0.259 0.535 0.001
OPL −0.371 0.034 −0.182 −0.276 0.001
ONL −0.398 0.022 −0.069 −0.318 0.036
PR 0.138 0.445 0.259 0.212 0.167
B
Univariate Analysis (Pearson
Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.769)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.257)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 22.966 — ,0.001 65.400 — ,0.001
BL BCVA 0.845 ,0.001 0.716 0.744 ,0.001
IVTs 0.141 0.435
Inner 0.387 0.026 0.043 0.184 0.045 0.085 0.359 0.026
Outer −0.418 0.016 −0.040 −0.216 0.020 −0.072 −0.392 0.016
*Adjusted coefﬁcient of multiple determination.
Signiﬁcant P values are in bold.
Dependent variable: Final best-corrected visual acuity.
Explanatory variables: Baseline best-corrected visual acuity (BL BCVA), number of intravitreal injections (IVTs), 1-year retinal nerve ﬁber layer thickness decrease (RNFL), 1-year
ganglion cell layer thickness decrease (GCL), 1-year inner plexiform layer thickness decrease (IPL), 1-year inner nuclear layer thickness decrease (INL), 1-year outer plexiform layer
thickness decrease (OPL), 1-year outer nuclear layer thickness decrease (ONL), 1-year photoreceptor–RPE-complex (PR) thickness decrease (external limiting membrane to Bruch’s
membrane).
Model including retinal layers individually (A), and aggregated as inner retinal layers (Inner = RNFL + GCL + IPL + INL) and outer retinal layers (Outer = OPL + ONL+PR), respectively
(B).
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Table 2. Inner Ring: Multivariate Forward Stepwise Regression Analysis of Factors With Inﬂuence on BCVA at the Last Follow-up in Eyes With DME Treated With
Ranibizumab
A
Univariate Analysis (Pearson Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.760)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.302)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 21.851 — ,0.001 70.577 — ,0.001
BL BCVA 0.845 ,0.001 0.732 0.760 ,0.001
IVTs 0.141 0.435
RNFL −0.003 0.988
GCL −0.015 0.934
IPL 0.075 0.677 0.371 0.142 0.115
INL 0.395 0.023
OPL −0.514 0.002 −0.230 −0.252 0.012 −0.476 −0.522 0.001
ONL −0.241 0.178
PR −0.271 0.128 −1.271 −0.284 0.064
B
Univariate Analysis (Pearson Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.728)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.109)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 21.178 — 0.001 68.815 — ,0.001
BL BCVA 0.845 ,0.001 0.773 0.803 ,0.001
IVTs 0.141 0.435
Inner 0.221 0.216
Outer −0.369 0.034 −0.054 −0.180 0.068 −0.112 −0.369 0.034
*Adjusted coefﬁcient of multiple determination.
Signiﬁcant P values are in bold.
Dependent variable: Final best-corrected visual acuity.
Explanatory variables: Baseline best-corrected visual acuity (BL BCVA), number of intravitreal injections (IVTs), 1-year retinal nerve ﬁber layer thickness decrease (RNFL), 1-year
ganglion cell layer thickness decrease (GCL), 1-year inner plexiform layer thickness decrease (IPL), 1-year inner nuclear layer thickness decrease (INL), 1-year outer plexiform layer
thickness decrease (OPL), 1-year outer nuclear layer thickness decrease (ONL), 1-year photoreceptor-retinal RPE-complex (PR) thickness decrease (external limiting membrane to
Bruch’s membrane).
Model including retinal layers individually (A), and aggregated as inner retinal layers (Inner = RNFL + GCL + IPL + INL) and outer retinal layers (Outer = OPL + ONL+PR), respectively
(B).
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Table 3. Central Subﬁeld: Multivariate Forward Stepwise Regression Analysis of Factors With Inﬂuence on BCVA Gain at the Last Follow-up in Eyes With DME
Treated With Ranibizumab
A
Univariate Analysis (Pearson Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.480)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.388)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 16.556 — 0.002 2.686 — 0.176
BL BCVA −0.341 0.052 −0.209 −0.383 0.007
IVTs −0.006 0.976
RNFL 0.245 0.169 0.203 0.298 0.093
GCL 0.007 0.969
IPL 0.359 0.041 0.195 0.440 0.002 0.123 0.279 0.099
INL 0.128 0.477
OPL −0.395 0.023 −0.131 −0.350 0.025 −0.109 −0.290 0.077
ONL −0.268 0.131
PR 0.424 0.014 0.194 0.280 0.069 0.290 0.418 0.015
B
Univariate Analysis (Pearson Correlation)
Multivariate Analysis including BL BCVA
(Adjusted R2 = 0.285)*
Multivariate Analysis excluding BL BCVA
(Adjusted R2 = 0.044)*
Correlation
Coefﬁcient r P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Unstandardized
Regression
Coefﬁcient B
Standardized
Regression
Coefﬁcient b P
Constant 22.966 — ,0.001 7.139 — ,0.001
BL BCVA −0.341 0.052 −0.284 −0.519 0.003
IVTs −0.006 0.976
Inner 0.221 0.217 0.043 0.324 0.045
Outer −0.273 0.125 −0.040 −0.381 0.020 −0.028 −0.273 0.125
*Adjusted coefﬁcient of multiple determination.
Signiﬁcant P values are in bold.
Dependent variable: Final best-corrected visual acuity.
Explanatory variables: Baseline best-corrected visual acuity (BL BCVA), number of intravitreal injections (IVTs), 1-year retinal nerve ﬁber layer thickness decrease (RNFL), 1-year
ganglion cell layer thickness decrease (GCL), 1-year inner plexiform layer thickness decrease (IPL), 1-year inner nuclear layer thickness decrease (INL), 1-year outer plexiform layer
thickness decrease (OPL), 1-year outer nuclear layer thickness decrease (ONL), 1-year photoreceptor-RPE-complex (PR) thickness decrease (external limiting membrane to Bruch’s
membrane).
Model including retinal layers individually (A), and aggregated as inner retinal layers (Inner = RNFL + GCL + IPL + INL) and outer retinal layers (Outer = OPL + ONL+PR), respectively
(B).
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http://links.lww.com/IAE/A415).31,32 In the eyes with
treated DME included in our study, there was some
possible thinning of the GCL, IPL and ONL. GCL
affection in diabetic patients has been previously
described as an early event accompanying hypergly-
cemia and the lack of insulin,33 and in association with
macular ischemia.14 Under hypoxic conditions, the
ONL thickness may be reduced because of metabolic
starvation and shrinkage of cell bodies. The photore-
ceptor–RPE complex thickness in our patients was not
obviously altered, which suggests that the behavior of
the ONL cannot be explained by photoreceptor
atrophy, which is not an early feature of diabetic ret-
inopathy. Nevertheless, photoreceptors consume a sub-
stantial amount of oxygen and may inﬂuence the
susceptibility to microvascular damage of the other
parts of the retina.34
To better assess the contribution of the individual
retinal layers to the model, baseline BCVA that in fact
accounts for more than half of the coefﬁcient of
determination, was omitted for subanalysis. Interest-
ingly, instead of the plexiform layers, the nuclear
layers were now more relevant as independent varia-
bles. It is conceivable, that the health state of the
nuclear layers is to some extent represented in baseline
BCVA. When this information is no longer directly
included in the model, the nuclear layers that implic-
itly carry information on the health of the neuronal
cells in the retina become more inﬂuential in the
regression model.
At ﬁrst glance, puzzling is the ﬁnding that in the
model predicting visual acuity gain, baseline BCVA
contributes negatively. However, this ﬁnding can be
explained by the ceiling effect, i.e., eyes starting with
good visual acuity gain fewer letters, because there is
less room for improvement. A similar ﬁnding has also
been reported in other studies, where patients with low
visual acuity at baseline gained more letters than
patients with better visual acuity at baseline.35 The
ﬁnding that a decrease of the photoreceptor–RPE com-
plex height is associated with visual acuity gain can be
well explained by the resolution of subretinal ﬂuid.
Limitations of this study include the retrospective
design and the small sample size. Moreover, auto-
mated segmentation of retina layers in pathologic
conditions is not reliable and, in the presence of retinal
distortion, prone to artifacts.36 The software algo-
rithms are manufacturer-speciﬁc and differences exist
between devices.37 Review of individual scans and
manual correction is necessary, adding a subjective
component to the quantiﬁcation. However, algorithms
still work better in conditions with relatively preserved
retinal architecture like DME than more destructive
degenerative disease such as age-related macular
degeneration.38 Moreover, retrospective analysis of
patients treated as needed following a visual acuity-
guided regimen carries the risk of positive selection
bias.
In conclusion, in this retrospective study we found
indirect morphological evidence for neurorecovery of
the outer retina during intravitreal treatment of DME
with ranibizumab. This recovery is presumably trig-
gered by improved metabolic supply after resolution of
intraretinal and subretinal ﬂuid.
Key words: anti-VEGF, diabetic macular edema,
layer segmentation, optical coherence tomography,
predictive, prognostic, ranibizumab, regression analy-
sis, retina.
References
1. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prev-
alence of visual impairment among adults in the United States.
Arch Ophthalmol 2004;122:477–485.
2. Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving
diabetes burden in the United States. Ann Intern Med 2004;
140:945–950.
3. The relationship of glycemic exposure (HbA1c) to the risk of
development and progression of retinopathy in the diabetes
control and complications trial. Diabetes 1995;44:968–983.
4. Wallow IH, Engerman RL. Permeability and patency of retinal
blood vessels in experimental diabetes. Invest Ophthalmol Vis
Sci 1977;16:447–461.
5. Browning DJ, Glassman AR, Aiello LP, et al. Optical coher-
ence tomography measurements and analysis methods in opti-
cal coherence tomography studies of diabetic macular edema.
Ophthalmology 2008;115:1366–1371.
6. Ebneter A, Wolf S, Zinkernagel MS. Prognostic signiﬁcance of
foveal capillary drop-out and previous panretinal photocoagu-
lation for diabetic macular oedema treated with ranibizumab.
Br J Ophthalmol In press.
7. Hee MR, Puliaﬁto CA, Duker JS, et al. Topography of diabetic
macular edema with optical coherence tomography. Ophthal-
mology 1998;105:360–370.
8. Brown DM, Nguyen QD, Marcus DM, et al. Long-term out-
comes of ranibizumab therapy for diabetic macular edema: the
36-month results from two phase III trials: RISE and RIDE.
Ophthalmology 2013;120:2013–2022.
9. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year out-
comes of individualized ranibizumab treatment in patients with
diabetic macular edema: the RESTORE extension study. Oph-
thalmology 2014;121:1045–1053.
10. Massin P, Bandello F, Garweg JG, et al. Safety and efﬁcacy of
ranibizumab in diabetic macular edema (RESOLVE Study):
a 12-month, randomized, controlled, double-masked, multicen-
ter phase II study. Diabetes Care 2010;33:2399–2405.
11. Sivaprasad S, Crosby-Nwaobi R, Esposti SD, et al. Structural
and functional measures of efﬁcacy in response to bevacizu-
mab monotherapy in diabetic macular oedema: exploratory
analyses of the BOLT study (report 4). PLoS One 2013;8:
e72755.
12. Byeon SH, Chu YK, Hong YT, et al. New insights into the
pathoanatomy of diabetic macular edema: angiographic pat-
terns and optical coherence tonography. Retina 2012;32:
1087–1099.
THINNER IS NOT ALWAYS BETTER  EBNETER ET AL 9
13. Rayess N, Rahimy E, Ying GS, et al. Baseline choroidal thick-
ness as a predictor for response to anti-vascular endothelial
growth factor therapy in diabetic macular edema. Am J Oph-
thalmol 2015;159:85–91.
14. Byeon SH, Chu YK, Lee H, et al. Foveal ganglion cell layer
damage in ischemic diabetic maculopathy: correlation of opti-
cal coherence tomographic and anatomic changes. Ophthal-
mology 2009;116:1949–1959.
15. Focal photocoagulation treatment of diabetic macular edema.
Relationship of treatment effect to ﬂuorescein angiographic
and other retinal characteristics at baseline: ETDRS report
no. 19. Early Treatment Diabetic Retinopathy Study Research
Group. Arch Ophthalmol 1995;113:1144–1155.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The
RESTORE study: ranibizumab monotherapy or combined with
laser versus laser monotherapy for diabetic macular edema.
Ophthalmology 2011;118:615–625.
17. Harris PA, Taylor R, Thielke R, et al. Research electronic data
capture (REDCap)—a metadata- driven methodology and
workﬂow process for providing translational research informat-
ics support. J Biomed Inform 2009;42:377–381.
18. R Core Team. R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria. Available at: http://www.R-project.org/. Accessed August
23, 2015.
19. Venables WN, Ripley BD. Modern Applied Statistics with S.
Fourth Edition. New York, NY: Springer, 2002.
20. Taiyun W. Corrplot: Visualization of a Correlation Matrix. R
package version 0.73. Available at: http://CRAN.R-project.
org/package=corrplot. Accessed November 12, 2014.
21. Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained
release of VEGF causes retinal neovascularization in rabbits
and breakdown of the blood-retinal barrier in rabbits and pri-
mates. Exp Eye Res 1997;64:505–517.
22. Casson RJ, Chidlow G, Ebneter A, et al. Translational neuro-
protection research in glaucoma: a review of deﬁnitions and
principles. Clin Exp Ophthalmol 2012;40:350–357.
23. Tan PE, Yu PK, Balaratnasingam C, et al. Quantitative confo-
cal imaging of the retinal microvasculature in the human retina.
Invest Ophthalmol Vis Sci 2012;53:5728–5736.
24. Lange CA, Bainbridge JW. Oxygen sensing in retinal health
and disease. Ophthalmologica 2012;227:115–131.
25. Linsenmeier RA. Electrophysiological consequences of
retinal hypoxia. Graefes Arch Clin Exp Ophthalmol 1990;
228:143–150.
26. Holfort SK, Klemp K, Kofoed PK, et al. Scotopic electro-
physiology of the retina during transient hyperglycemia in
type 2 diabetes. Invest Ophthalmol Vis Sci 2010;51:2790–
2794.
27. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental
oxygen improves diabetic macular edema: a pilot study. Invest
Ophthalmol Vis Sci 2004;45:617–624.
28. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-
retinal barrier breakdown in early diabetes. Invest Ophthalmol
Vis Sci 2001;42:2408–2413.
29. Dooley I, Treacy M, O’Rourke M, et al. Serial spectral domain
ocular coherence tomography measurement of outer nuclear
layer thickness in rhegmatogenous retinal detachment repair.
Curr Eye Res 2015;40:1073–1076.
30. Menke MN, Kowal JH, Dufour P, et al. Retinal layer measure-
ments after successful macula-off retinal detachment repair
using optical coherence tomography. Invest Ophthalmol Vis
Sci 2014;55:6575–6579.
31. Demirkaya N, van Dijk HW, van Schuppen SM, et al. Effect of
age on individual retinal layer thickness in normal eyes as
measured with spectral-domain optical coherence tomography.
Invest Ophthalmol Vis Sci 2013;54:4934–4940.
32. Ehnes A, Wenner Y, Friedburg C, et al. Optical coherence
tomography (OCT) device independent intraretinal layer seg-
mentation. Transl Vis Sci Technol 2014;3:1.
33. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the
retina during experimental and human diabetes. Early onset
and effect of insulin. J Clin Invest 1998;102:783–791.
34. Kern TS, Berkowitz BA. Photoreceptors in diabetic retinopa-
thy. J Diabetes Investig 2015;6:371–380.
35. Wells JA, Glassman AR, Ayala AR, et al. Aﬂibercept, beva-
cizumab, or ranibizumab for diabetic macular edema. N Engl J
Med 2015;372:1193–1203.
36. Ray R, Stinnett SS, Jaffe GJ. Evaluation of image artifact pro-
duced by optical coherence tomography of retinal pathology.
Am J Ophthalmol 2005;139:18–29.
37. Lammer J, Scholda C, Prunte C, et al. Retinal thickness and
volume measurements in diabetic macular edema: a comparison
of four optical coherence tomography systems. Retina 2011;
31:48–55.
38. Waldstein SM, Gerendas BS, Montuoro A, et al. Quantitative
comparison of macular segmentation performance using
identical retinal regions across multiple spectral-domain opti-
cal coherence tomography instruments. Br J Ophthalmol
2015;99:794–800.
10 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES  2015  VOLUME 0  NUMBER 0
